AstraZeneca Plc’s 2 Greatest Weaknesses

Two standout factors undermining an investment in AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AZNWhen I think of pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US), two factors jump out at me as the firm’s greatest weaknesses and top the list of what makes the company less attractive as an investment proposition.

1) Loss of product exclusivity

It takes a lot of time and expensive to get a new drug from the test tube to the chemist’s sales shelf. The process takes years and many compounds don’t cut it, causing scientists to drop them along the way. So, when a new drug complies with safety standards and proves effective as a treatment, the law allows the developing firm patent protection, which helps the company recoup its expenses and generate profit from its sales without other companies undercutting the price with copycat competition.

However, patents run out over time, generic competition swoops in, and once stalwart profit-earning products stop generating the returns they once did. Such is the case with AstraZeneca, which has seen several of its key earners attacked on price by competing products because exclusivity has timed-out.

2) Crimped profitability

AstraZeneca’s CEO reckons that loss of exclusivity, the so-called patent cliff, will continue to thump the firm’s financial results in the ‘near term’. Now, I’m unclear about the timescales here, but the damage inflicted by several of AstraZeneca’s key brands coming off patent is clear to see over a period of years:

Year   to December 2009 2010 2011 2012 2013
Revenue ($m) 32,804 33,269 33,591 27,973 25,711
Adjusted earnings per share (cents) 632 671 728 641 505

Revenue and profits are heading down.

The revenue slide seems unlikely to stop any time soon. In fact, the CEO says revenues will likely return to 2013 levels in 2017. That doesn’t sound good for 2014, 2015 and 2016, then. Investors will need to run on faith for some time yet before the finances confirm the wisdom of an investment in AstraZenecca.

What now?

Right now AstraZeneca seems to attract mainly as a turnaround proposition. It’s conceivable that a return to growth could occur as new products take off.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin does not own shares in AstraZeneca.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

3 UK stocks I reckon could benefit from the upcoming general election

As the general election hurtles towards us, this Fool wonders which UK stocks could benefit, and focuses on three picks…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

At 11%, this dividend share pays the biggest yield in the FTSE 100

When a dividend share offers a big yield, we need to be cautious of the risks. But I reckon this…

Read more »

British Isles on nautical map
Investing Articles

I reckon Hiscox shares could be one of the best bargains on the FTSE

I've been investing in FTSE companies for years, but after a major decline I've not seen a company with as…

Read more »

Grey Number 4 Stencil on Yellow Concrete Wall
Investing Articles

4 reasons I’d still buy National Grid shares in a heartbeat despite the recent wobble!

As National Grid shares plunged on the news of a right issue, I’m not flinching, and reckon it's a top…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After gaining 45% in 12 months, is the Amazon share price now overvalued?

Our author thinks the Amazon share price might be too high. While the long-term future of the business looks bright,…

Read more »

Investing Articles

2 hot dividend stocks I’d buy and hold for 10 years

Our writer reckons these two dividend stocks could help her bag juicy dividends for years to come and explains why.

Read more »

British Pennies on a Pound Note
Investing Articles

2 dividend-paying penny shares I’d happily own

These two penny shares have caught our writer's eye for a combination of income prospects now and business growth potential…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This FTSE 250 share looks like a bargain to me!

This FTSE 250 share has seen its price tumble due to chaotic local economic conditions in a key market. But…

Read more »